Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1999 May 18;160(10):1449–1455.

Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease

S Perreault 1, M Dorais 1, L Coupal 1, G Paradis 1, M R Joffres 1, S A Grover 1
PMCID: PMC1232605  PMID: 10352634

Abstract

OBJECTIVE: To compare the prevalence of modifiable risk factors for cardiovascular disease among hypertensive and nonhypertensive adults and to estimate the effect of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. METHODS: The authors evaluated a sample of 7814 subjects aged 35-74 years free of clinical cardiovascular disease from the Canadian Heart Health Surveys to estimate the prevalence of cardiovascular risk factors. They identified hyperlipidemic subjects (ratio of total cholesterol to high-density lipoprotein cholesterol [total-C/HDL-C] 6.0 [corrected] or more for men and 5.0 [corrected] or more for women) and hypertensive subjects (systolic or diastolic blood pressure 160/90 mm Hg or greater, or receiving pharmacologic or nonpharmacologic treatment). A life expectancy model was used to estimate the rate of death from coronary artery disease following specific treatments. RESULTS: An elevated total-C/HDL-C ratio was significantly more common among hypertensive than nonhypertensive men aged 35-64 (rate ratio [RR] 1.56 for age 35-54, 1.28 for age 55-64) and among hypertensive than nonhypertensive women of all ages (RR 2.73 for age 35-54, 1.58 for age 55-64, 1.31 for age 65-74). Obesity and a sedentary lifestyle were also more common among hypertensive than among nonhypertensive subjects. According to the model, more deaths from coronary artery disease could be prevented among subjects with treated but uncontrolled hypertension by modifying lipids rather than by further reducing blood pressure for men aged 35-54 (reduction of 50 v. 29 deaths per 100,000) and 55-64 (reduction of 171 v. 104 deaths per 100,000) and for women aged 35-54 (reduction of 44 v. 39 deaths per 100,000). Starting antihypertensive therapy in subjects aged 35-74 with untreated hypertension would achieve a greater net reduction in deaths from coronary artery disease than would lipid lowering. Nonetheless, the benefits of lipid therapy were substantial: lipid intervention among hypertensive subjects aged 35-74 represented 36% of the total benefits of treating hyperlipidemia in the total hyperlipidemic population. INTERPRETATION: The clustering of hyperlipidemia and the potential benefits of treatment among hypertensive adults demonstrate the need for screening and treating other cardiovascular risk factors beyond simply controlling blood pressure.

Full Text

The Full Text of this article is available as a PDF (152.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson K. M., Odell P. M., Wilson P. W., Kannel W. B. Cardiovascular disease risk profiles. Am Heart J. 1991 Jan;121(1 Pt 2):293–298. doi: 10.1016/0002-8703(91)90861-b. [DOI] [PubMed] [Google Scholar]
  2. Assmann G., Schulte H. Diabetes mellitus and hypertension in the elderly: concomitant hyperlipidemia and coronary heart disease risk. Am J Cardiol. 1989 May 2;63(16):33H–37H. doi: 10.1016/0002-9149(89)90113-6. [DOI] [PubMed] [Google Scholar]
  3. Assmann G., Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988 Dec;116(6 Pt 2):1713–1724. doi: 10.1016/0002-8703(88)90220-7. [DOI] [PubMed] [Google Scholar]
  4. Bradford R. H., Shear C. L., Chremos A. N., Dujovne C., Downton M., Franklin F. A., Gould A. L., Hesney M., Higgins J., Hurley D. P. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991 Jan;151(1):43–49. doi: 10.1001/archinte.151.1.43. [DOI] [PubMed] [Google Scholar]
  5. Bulpitt C. J., Beevers D. G., Butler A., Coles E. C., Hunt D., Munro-Faure A. D., Newson R. B., O'Riordan P. W., Petrie J. C., Rajagopalan B. The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP). J Hypertens. 1986 Feb;4(1):93–99. doi: 10.1097/00004872-198602000-00015. [DOI] [PubMed] [Google Scholar]
  6. Cleeman J. I., Grundy S. M. National Cholesterol Education Program recommendations for cholesterol testing in young adults. A science-based approach. Circulation. 1997 Mar 18;95(6):1646–1650. doi: 10.1161/01.cir.95.6.1646. [DOI] [PubMed] [Google Scholar]
  7. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N. H., Eberlein K. A., Godwin J., Qizilbash N., Taylor J. O., Hennekens C. H. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990 Apr 7;335(8693):827–838. doi: 10.1016/0140-6736(90)90944-z. [DOI] [PubMed] [Google Scholar]
  8. Ford E. S., DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Am J Epidemiol. 1991 Jun 15;133(12):1220–1230. doi: 10.1093/oxfordjournals.aje.a115834. [DOI] [PubMed] [Google Scholar]
  9. Grover S. A., Coupal L., Hu X. P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA. 1995 Sep 13;274(10):801–806. [PubMed] [Google Scholar]
  10. Grover S. A., Paquet S., Levinton C., Coupal L., Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med. 1998 Mar 23;158(6):655–662. doi: 10.1001/archinte.158.6.655. [DOI] [PubMed] [Google Scholar]
  11. Haynes R. B., Lacourcière Y., Rabkin S. W., Leenen F. H., Logan A. G., Wright N., Evans C. E. Report of the Canadian Hypertension Society Consensus Conference: 2. Diagnosis of hypertension in adults. CMAJ. 1993 Aug 15;149(4):409–418. [PMC free article] [PubMed] [Google Scholar]
  12. Joffres M. R., Ghadirian P., Fodor J. G., Petrasovits A., Chockalingam A., Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens. 1997 Oct;10(10 Pt 1):1097–1102. doi: 10.1016/s0895-7061(97)00224-0. [DOI] [PubMed] [Google Scholar]
  13. Joffres M. R., Hamet P., Rabkin S. W., Gelskey D., Hogan K., Fodor G. Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ. 1992 Jun 1;146(11):1997–2005. [PMC free article] [PubMed] [Google Scholar]
  14. Kannel W. B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996 May 22;275(20):1571–1576. [PubMed] [Google Scholar]
  15. Kannel W. B., D'Agostino R. B., Stepanians M., D'Agostino L. C. Efficacy and tolerability of lovastatin in a six-month study: analysis by gender, age and hypertensive status. Am J Cardiol. 1990 Sep 18;66(8):1B–10B. doi: 10.1016/0002-9149(90)90434-3. [DOI] [PubMed] [Google Scholar]
  16. Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994 Nov 1;121(9):641–647. doi: 10.7326/0003-4819-121-9-199411010-00002. [DOI] [PubMed] [Google Scholar]
  17. Laurenzi M., Mancini M., Menotti A., Stamler J., Stamler R., Trevisan M., Zanchetti A. Multiple risk factors in hypertension: results from the Gubbio study. J Hypertens Suppl. 1990 Mar;8(1):S7–12. doi: 10.1097/00004872-199003001-00003. [DOI] [PubMed] [Google Scholar]
  18. Law M. R., Wald N. J., Thompson S. G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994 Feb 5;308(6925):367–372. doi: 10.1136/bmj.308.6925.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Law M. R., Wald N. J., Wu T., Hackshaw A., Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994 Feb 5;308(6925):363–366. doi: 10.1136/bmj.308.6925.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. MacLean D. R., Petrasovits A., Nargundkar M., Connelly P. W., MacLeod E., Edwards A., Hessel P. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. CMAJ. 1992 Jun 1;146(11):1969–1974. [PMC free article] [PubMed] [Google Scholar]
  21. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765–774. doi: 10.1016/0140-6736(90)90878-9. [DOI] [PubMed] [Google Scholar]
  22. Manninen V., Elo M. O., Frick M. H., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988 Aug 5;260(5):641–651. [PubMed] [Google Scholar]
  23. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  24. Samuelsson O. Hypertension in middle-aged men. Management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand Suppl. 1985;702:1–79. [PubMed] [Google Scholar]
  25. Samuelsson O., Wilhelmsen L., Andersson O. K., Pennert K., Berglund G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden. JAMA. 1987 Oct 2;258(13):1768–1776. [PubMed] [Google Scholar]
  26. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  27. Wikstrand J., Warnold I., Olsson G., Tuomilehto J., Elmfeldt D., Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988 Apr 1;259(13):1976–1982. [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES